Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Overview:

The global ischemic heart disease (IHD) drugs market size reached US$ 6.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.9 Billion by 2028, exhibiting a growth rate (CAGR) of 4.4% during 2023-2028.

Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global ischemic heart disease (IHD) drugs market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on disease class and drug class.

Breakup by Disease Class:

Angina Pectoris
Myocardial Infarction

Breakup by Drug Class:

Anti-Dyslipidemic Drugs
Calcium Channel Blockers
Beta-Blockers
ACE Inhibitors
ARBs
Vasodilators
Antithrombotic Agents

Breakup by Region

North America
Europe
Asia Pacific
Middle East and Africa
Latin America

Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

Key Questions Answered in This Report:
How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global ischemic heart disease (IHD) drugs market?
What is the breakup of the market based on the disease class?
What is the breakup of the market based on the drug class?
What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?